期刊文献+

硫唑嘌呤致克罗恩病患者急性胰腺炎 被引量:2

Acute pancreatitis induced by azathioprine in patient with Crohn's disease
原文传递
导出
摘要 1例29岁女性患者因克罗恩病口服泼尼松治疗,初始剂量40 mg/d,3个月后减量至25 mg/d,因病情出现反复,泼尼松恢复初始剂量并加服硫唑嘌呤50 mg/d。23 d后,患者出现持续性右上腹疼痛伴恶心呕吐,实验室检查示WBC 13.4×10^9/L、中性粒细胞0.86、嗜酸粒细胞计数0.41×10^9/L、血清淀粉酶336 U/L、血清脂肪酶1 084 U/L,腹部CT示胰腺尾部渗出伴周围脂肪间隙模糊。考虑为硫唑嘌呤所致急性胰腺炎。停用硫唑嘌呤和泼尼松,禁食、水,并予液体复苏、抑制胰酶分泌、止痛等对症治疗。治疗第8天,患者腹痛基本消失,无恶心呕吐,血清淀粉酶63 U/L,血清脂肪酶 47 U/L。第10天,调整克罗恩病治疗方案为肌内注射甲氨蝶呤25 mg、1次/周,口服泼尼松40 mg、1次/d。随访3个月,患者未再出现上腹持续隐痛和呕吐等症状。 A 29-year-old female patient with Crohn′s disease received prednisone orally. The initial dose was 40 mg daily, then gradually decreased to 25 mg daily after 3 months. Because of recurrence of her illness, the dose prednisone was restored to the initial level and azathioprine (50 mg daily) was added. After 23 days, the patient developed persistent abdominal pain with nausea and vomiting. Laboratory tests showed the following values: white blood cell 13.4×10^9/L, neutrophile granulocyte 86.3%, eosinophil count 0.41×10^9/L, serum amylase 336 U/L, serum lipase 1 084 U/L. The result of abdominal CT showed exudation in pancreas tail, with fuzzy images in surrounding fat spaces. The patient was diagnosed as acute pancreatitis induced by azathioprine. Azathioprine and prednisone were stopped, and the patient received fasting, fluid resuscitation, inhibition of pancreatic secretion, and analgesic. On day 8 of symptomatic treatment, the patient′s abdominal symptom disappeared, without nausea and vomiting. The result of laboratory tests showed serum amylase 63 U/L, serum lipase 47 U/L. On day 10, the treatment of Crohn′s disease was adjusted to intramuscular injection of methotrexate 25 mg once a week, and oral prednisone 40 mg daily. The results of following up for 3 months showed that the patient did not show symptoms of vomiting and persistent pain in the upper abdomen.
出处 《药物不良反应杂志》 CSCD 2018年第1期60-61,共2页 Adverse Drug Reactions Journal
关键词 硫唑嘌呤 胰腺炎 Azathioprine Pancreatitis
  • 相关文献

参考文献3

二级参考文献53

  • 1Winter JW,Gaffney D,Shapiro D,et al.Assessment of thiopurine methyhransferase enzyme activity is superior to genotype in predicting myelosuppression following azathioprine therapy in patients with inflammatory bowel disease.Aliment Pharmacol Ther,2007,25(9):1069-1077.
  • 2Yates CR,Krynetski EY,Loennechen T,et al.Molecular diagnosis of thiopurine S-methyltransferase deficiency:genetic basis for azathioprine and mercaptopurine intolerance.Ann Intern Med,1997,126(8):608-614.
  • 3Ansari A,Arenas M,Greenfield SM,et al.Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of inflammatory bowel disease.Aliment Pharmacol Ther,2008,28(8):973-983.
  • 4Ban H,Andoh A,Tanaka A,et al.Analysis of thiopurine S-methyltransferase genotypes in Japanese patients with inflammatory bowel disease.Intern Med,2008,47(19):1645-1648.
  • 5Stoeco G,Martelossi S,Barabino A,et al.Glutathione-S-transferase genotypes and the adverse effects of azathioprine in young patients with inflammatory bowel disease.Inflamm Bowel Dis,2007,13(1):57-64.
  • 6Palmieri O,Latiano A,Bossa F,et al.Sequential evaluation of thiopurine methyltransferase,inosine triphosphate pyrophosphatase,and HPRT1 genes polymorphisms to explain thiopurines'toxicity and efficacy.Aliment Pharmacol Ther,2007,26(5):737-745.
  • 7Zelinkova Z,Derijks LJ,Stokkers PC,et al.Inosine triphosphate pyrophosphatase and thiopurine smethyltransferase genotypes relationship to azathioprineinduced myelosuppression.Clin Gastroenterol Hepatol,2006,4(1):44-49.
  • 8Hindorf U,Lindqvist M,Peterson C,et al.Pharmacogenetics during standardised initiation of thiopurine treatment in inflammatory bowel disease.Gut,2006,55(10):1423-1431.
  • 9Schwab M,Sch(a)ffeler E,Marx C,et al.Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease:impact of thiopurine Smethyhransferase polymorphism.Pharmacogenetics,2002,12(6):429-436.
  • 10Hawwa AF,Millership JS,Collier PS,et al.Pharmacogenomic studies of the anticancer and immunosuppressive thiopurinesmercaptopurineand azathioprine.Br J Clin Pharmacol,2008,66(4):517-528.

共引文献39

同被引文献3

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部